Penicillin: the medicine with the greatest impact on therapeutic outcomes

Mini-Review

Abstract

The principal point of this paper is that the discovery of penicillin and the development of the supporting technologies in microbiology and chemical engineering leading to its commercial scale production represent it as the medicine with the greatest impact on therapeutic outcomes. Our nomination of penicillin for the top therapeutic molecule rests on two lines of evidence concerning the impact of this event: (1) the magnitude of the therapeutic outcomes resulting from the clinical application of penicillin and the subsequent widespread use of antibiotics and (2) the technologies developed for production of penicillin, including both microbial strain selection and improvement plus chemical engineering methods responsible for successful submerged fermentation production. These became the basis for production of all subsequent antibiotics in use today. These same technologies became the model for the development and production of new types of bioproducts (i.e., anticancer agents, monoclonal antibodies, and industrial enzymes). The clinical impact of penicillin was large and immediate. By ushering in the widespread clinical use of antibiotics, penicillin was responsible for enabling the control of many infectious diseases that had previously burdened mankind, with subsequent impact on global population demographics. Moreover, the large cumulative public effect of the many new antibiotics and new bioproducts that were developed and commercialized on the basis of the science and technology after penicillin demonstrates that penicillin had the greatest therapeutic impact event of all times.

Keywords

Penicillins Antibiotics β-Lactams Cephalosporins Carbapenems 

Notes

Acknowledgments

A considerable portion of this review derives from statements made directly by Professor Ernst Chain to one of the authors (NK), who was a graduate student under Professor Chain at Imperial College, London, in 1973–1974.

References

  1. Abraham EP, Newton GGF (1961) The structure of cephalosporin C. Biochem J 79:377–393Google Scholar
  2. Abraham EP, Newton GGF, Hale CW (1954) Isolation and some properties of cephalosporin N, a new penicillin. Biochem J 58:94–102Google Scholar
  3. Abraham EP, Newton GGF, Schenck JR, Hargie MP, Olson BH, Schuurmans DM, Fisher MW, Fusari SA (1955) Identity of cephalosporin N and synnematin B. Nature 176:551CrossRefGoogle Scholar
  4. Arnstein HRV, Morris D (1960) The structure of a peptide containing α-aminoadipic acid, cysteine and valine, present in the mycelium of Penicillium chrysogenum. Biochem J 76:357–361Google Scholar
  5. Aryanchira S (2010) Overcoming antibiotic-resistant bacteria. Gen Eng Biotechnol News 30(15):18Google Scholar
  6. Banko G, Demain AL, Wolfe S (1987) α-(L-α-Aminoadipyl)-L-cysteinyl-D-valine synthetase (ACV synthetase): a multifunctional enzyme with broad substrate specificity for the synthesis of penicillin and cephalosporin precursors. J Amer Chem Soc 109:2858–2860CrossRefGoogle Scholar
  7. Batchelor FR, Doyle FP, Nayler JHC, Rolinson GN (1959) Synthesis of penicillin: 6-amino-penicillanic acid in penicillin fermentations. Nature 183:257–258CrossRefGoogle Scholar
  8. Bost PE, Demain AL (1977) Studies on the cell-free biosynthesis of β-lactam antibiotics. Biochem J 162:681–687Google Scholar
  9. Brotzu G (1948) Richerche su di un nova antibiotic. Lavori delll'Instituto d'Igienee di Cagliari 1–11Google Scholar
  10. Burton HS, Abraham EP (1951) Isolation of antibiotics from a species of Cephalosporium. Cephalosporins P1, P2, P3, P4 and P5. Biochem J 50:168–174Google Scholar
  11. Crawford K, Heatley NG, Boyd PF, Hale CW, Kelly BK, Miller GA, Smith N (1952) Antibiotic production by a species of Cephalosporium. J Gen Microbiol 6:47–59Google Scholar
  12. Davey YF, Johnson MJ (1953) Penicillin production in corn steep media with continuous carbohydrate addition. Appl Microbiol 1:208–211Google Scholar
  13. Demain AL (1957) Inhibition of penicillin formation by lysine. Arch Biochem Biophys 67:244–246CrossRefGoogle Scholar
  14. Demain AL (1963) L-Valine: a precursor of cephalosporin C. Biochem Biophys Res Commun 10:45–48CrossRefGoogle Scholar
  15. Demain AL, Masurekar PS (1974) Lysine inhibition of in vivo homocitrate synthesis in Penicillum chysogenum. J Gen Microbiol 82:143–151Google Scholar
  16. Dixon B (2006) Sulfa's true significance. Microbe 1:500–501Google Scholar
  17. Fawcett PA, Usher JJ, Abraham EP (1976) Aspects of cephalosporin and penicillin biosynthesis. In: MacDonald KD (ed) Second international symposiumon on the genetics of industrial microorganisms. Academic Press, New York. pp 129–138Google Scholar
  18. Fleming A (1929) On the antibacterial action of a Penicillium, with special reference to their use in the isolation of B. influenza. Brit J Exp Pathol 10:226–236Google Scholar
  19. Florey HW, Chain EB, Heatley NG, Jennings MA, Sanders AG, Abraham EP, Florey ME (1949) Antibiotics, vol 2. Oxford University Press, LondonGoogle Scholar
  20. Friedrich CG, Demain AL (1977) Effects of lysine analogs on Penicillium chrysogenum. Appl Environ Microbiol 34:706–709Google Scholar
  21. Gottshall RY, Roberts JM, Portwood LM, Jennings JC (1951) Synnematin, an antibiotic produced by Tilachlidium. Proc Soc Exp Biol Med 76:307–311Google Scholar
  22. Hollander IJ, ShenY-Q HJ, Demain AL, Wolfe S (1984) A pure enzyme catalyzing penicillin biosynthesis. Science 224:610–612CrossRefGoogle Scholar
  23. Jarvis FG, Johnson MJ (1947) The role of the constituents of synthetic media for penicillin production. J Amer Chem Soc 69:3010–3018CrossRefGoogle Scholar
  24. Johnson MJ (1952) Recent advances in the penicillin fermentation. Bull World Hlth Org 6:99–121Google Scholar
  25. Kahan FS, Kahan FM, Goegelman RT, Currie SA, Jackson M, Stapley EO, Miller TW, Miller AK, Hendlin D, Mochales S, Hernandez S, Woodruff HB, Birnbaum J (1979) Thienamycin, a new β-lactam antibiotic. I. Discovery, taxonomy, isolation, and physical properties. J Antibiot 32:1–12Google Scholar
  26. Kato K (1953) Occurrence of penicillin-nucleus in culture broths. J Antibiot Ser A 6:184–185Google Scholar
  27. Kohsaka M, Demain AL (1976) Conversion of penicillin N to cephalosporin(s) by cell-free extracts of Cephalosporium acremonium. Biochem Biophys Res Commun 70:465–473CrossRefGoogle Scholar
  28. Lechevalier H, Acker RF, Corke CT, Haenseler CM, Waksman SA (1953) Candicidin, a new antifungal antibiotic. Mycologia 45:155–171Google Scholar
  29. Miller GA, Kelly BK, Newton GGF (1956) Cephalosporin production. British patent 759,624Google Scholar
  30. Miller IM, Stapley EO, Chaiet L (1962) Production of synnematin B by a member of the genus Streptomyces. Bacteriol Proc 49:32Google Scholar
  31. Moyer AJ, Coghill RD (1946) Penicillin. IX. The laboratory scale production of penicillin in submerged cultures by Penicillium notatum Westling (NRRL 832). J Bacteriol 51:79–93Google Scholar
  32. Nagarajan R, Boeck LD, Gorman M, Hamill RL, Higgens CH, Hoehn MM, Stark WM, Whitney JG (1971) β-Lactam antibiotics from Streptomyces. J Amer Chem Soc 93:2308–2310CrossRefGoogle Scholar
  33. Olano C, Lombo F, Mendez C, Salas JA (2008) Improving production of bioactive secondary metabolites in actinomycetes by metabolic engineering. Metab Eng 10:281–292CrossRefGoogle Scholar
  34. Raper KB (1994) The development of improved penicillin-producing molds. Ann NY Acad Sci 48:41–56CrossRefGoogle Scholar
  35. Reed JC (2011) NCATS could mitigate pharma valley of death. National Center for Advancing Translational Sciences essential to capitalize on basic research. Gen Eng Biotechnol News 31(10):6–8Google Scholar
  36. Roberts JM (1952) Antibiotic substances produced by species of Cephalosporium with a description of new species. Mycologia 44:292–306Google Scholar
  37. Schatz A, Bugie E, Waksman SA (1944) Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exptl Biol Med 55:66–69Google Scholar
  38. Somerson NL, Demain AL, Nunheimer TD (1961) Reversal of lysine inhibition of penicillin production by α-aminoadipioc acid or adipic acid. Arch Biochem Biophys 93:238–241CrossRefGoogle Scholar
  39. Spizek J, Novotna J, Rezanka T, Demain AL (2010) Do we need new antibiotics? The search for new targets and new compounds. J Ind Microbiol Biotechnol 37:1241–1248CrossRefGoogle Scholar
  40. Stapley EO, Jackson M, Hernandez S, Zimmerman SB, Currie SA, Mochales S, Mata JM, Woodruff HB, Hendlin D (1972) Cephamycins, a new family of β-lactam antibiotics. I. Production by actinomycetes, including Streptomyces lactamdurans sp. n. Antimicrob Agents Chemother 2:122–131Google Scholar
  41. Trown PW, Abraham EP, Newton GGG, Hale CW, Miller GA (1962) Incorporation of acetate into cephalosporin C. Biochem J 84:157–166Google Scholar
  42. Trown PW, Sharp M, Abraham EP (1963) α-Oxoglutarate as a precursor of the D-α-aminoadipic residue in cephalosporin C. Biochem J 86:280–284Google Scholar
  43. Waksman SA, Lechevalier HA (1949) Neomycin, a new antibiotic against streptomycin-resistant bacteria, including tuberculosis organisms. Science 109:305–307CrossRefGoogle Scholar
  44. Waksman SA, Woodruff HB (1940) Bacteriostatic and bactericidal substances produced by a soil actinomyces. Proc Soc Exptl Biol Med 45:609–614Google Scholar
  45. Weissmann G (2011) Is drug development too slow? NIH to the rescue! FASEB J 25:1110–1122Google Scholar
  46. Yoshida M, Konomi T, Kohsaka M, Baldwin JE, Herchen S, Singh P, Hunt NA, Demain AL (1978) Cell-free ring expansion of penicillin N to deacetoxycephalosporin C by Cephalosporium acremonium CW-19 and its mutants. Proc Natl Acad Sci USA 75:6253–6257CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.CoatesvilleUSA
  2. 2.Charles A. Dana Research Institute for Scientists Emeriti (R.I.S.E.)Drew UniversityMadisonUSA

Personalised recommendations